These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9814057)

  • 1. [Antineoplastic chemotherapy (hormone therapy included): classification, main secondary effects].
    Brun B; Piedbois P
    Rev Prat; 1998 Sep; 48(14):1587-600. PubMed ID: 9814057
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anticancer chemotherapy (including hormone therapy). Classification, mode of action, main side effects].
    Brun B; Piedbois P
    Rev Prat; 1994 Nov; 44(17):2367-77. PubMed ID: 7984948
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of cancer chemotherapy. The discovery of new active drugs. II].
    Lopez M
    Clin Ter; 1998; 149(6):453-9. PubMed ID: 10100409
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of hormone-refractory disease.
    Hennequin C
    BJU Int; 2004 Dec; 94 Suppl 3():16-7. PubMed ID: 15521889
    [No Abstract]   [Full Text] [Related]  

  • 5. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in chemotherapy options for metastatic breast cancer: introduction of epothilones.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):29-30. PubMed ID: 17824553
    [No Abstract]   [Full Text] [Related]  

  • 7. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
    Ghosn M; Kattan J; Younes F
    Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
    [No Abstract]   [Full Text] [Related]  

  • 8. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current role of chemotherapy in the treatment of hormone-resistant prostatic cancer].
    Soulie M; Beuzeboc P; Irani J; Davin JL
    Prog Urol; 2006 Jun; 16(3):394-5. PubMed ID: 16821362
    [No Abstract]   [Full Text] [Related]  

  • 10. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Apoptosis and chemotherapy].
    Bettaieb A; Sordet O; Belon JP; Solary E
    Bull Cancer; 1999 Jan; 86(1):41-6. PubMed ID: 10029703
    [No Abstract]   [Full Text] [Related]  

  • 12. [Problems in oncologic pharmacology].
    Filov VA; Gershanovich ML; Akimov MA; Akimov AA
    Vopr Onkol; 1998; 44(6):651-61. PubMed ID: 10087958
    [No Abstract]   [Full Text] [Related]  

  • 13. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
    Ward JF
    Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic testing for sensitivity of breast cancer to hormonal therapy.
    Symmans WF
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1954-5. PubMed ID: 16609001
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming drug resistance in patients with metastatic breast cancer.
    Wong ST; Goodin S
    Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
    Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.